8-KLeadership ChangesCorporate ChangesExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Executive Changes (Oct 15, 2004)

Filed October 15, 2004For Securities:ABT

Summary

This 8-K filing from Abbott Laboratories (ABT) on October 15, 2004, primarily reports on two key corporate governance changes. Firstly, the company announced the appointment of William M. Daley, a prominent figure from JPMorgan Chase & Co., to its Board of Directors. This addition could signal a strengthening of the board's expertise, particularly given Mr. Daley's background in finance and business leadership. Secondly, the filing details an amendment to Abbott's bylaws, increasing the size of the Board of Directors from thirteen to fourteen members. This increase, effective October 8, 2004, allows for the expansion of the board, potentially to accommodate new directors like Mr. Daley and to provide greater capacity for oversight and strategic guidance. Investors should note the appointment of a director from a major financial institution that also provides services to Abbott.

Key Highlights

  • 1William M. Daley, Chairman of Midwest for JPMorgan Chase & Co., appointed to Abbott's Board of Directors.
  • 2Mr. Daley's appointment became effective immediately on October 8, 2004.
  • 3Abbott Laboratories' Board of Directors size was increased from thirteen to fourteen members.
  • 4The amendment to the bylaws regarding board size was effective October 8, 2004.
  • 5JPMorgan Chase & Co. provides commercial banking services to Abbott.
  • 6The filing includes the press release announcing Mr. Daley's appointment as an exhibit.
  • 7The filing also includes the amended and restated bylaws as an exhibit.

Frequently Asked Questions

William M. Daley is the Chairman of Midwest for JPMorgan Chase & Co. His appointment to Abbott's Board of Directors is significant due to his extensive experience in finance and business leadership from a major financial institution. The board has not yet determined his committee assignments.

Abbott Laboratories' Board of Directors size was increased from thirteen to fourteen members through an amendment to the company's bylaws, effective October 8, 2004.

Yes, the filing notes that JPMorgan Chase & Co. has provided commercial banking services to Abbott Laboratories during 2004.

Increasing the board size can allow for greater diversity of skills and experience, accommodate new directors, and potentially enhance the board's capacity for oversight and strategic decision-making. In this case, it facilitated the addition of Mr. Daley.